Serious (grade 3-4) adverse events with tipifarnib, by CTC version 2.0
| Adverse event . | No. of patients (%) . |
|---|---|
| Drug-related, serious adverse events | 74 (47) |
| Death with drug-related adverse event as cause of death | |
| Total | 1 (1) |
| Within 30 d of first dose | 0 (0) |
| After 30 d of first dose | 1 (1) |
| Category | |
| Constitutional | 8 (5) |
| Dermatology/skin | 10 (6) |
| Gastrointestinal | 18 (11) |
| Hepatic | 5 (3) |
| Infection/febrile neutropenia | 35 (22) |
| Metabolic/laboratory | 8 (5) |
| Neurologic | 13 (8) |
| Renal/genitourinary | 4 (2) |
| Adverse event . | No. of patients (%) . |
|---|---|
| Drug-related, serious adverse events | 74 (47) |
| Death with drug-related adverse event as cause of death | |
| Total | 1 (1) |
| Within 30 d of first dose | 0 (0) |
| After 30 d of first dose | 1 (1) |
| Category | |
| Constitutional | 8 (5) |
| Dermatology/skin | 10 (6) |
| Gastrointestinal | 18 (11) |
| Hepatic | 5 (3) |
| Infection/febrile neutropenia | 35 (22) |
| Metabolic/laboratory | 8 (5) |
| Neurologic | 13 (8) |
| Renal/genitourinary | 4 (2) |